Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Sponsor: Uppsala University
Summary
This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.
Official title: Bortezomib-bendamustine-melphalan vs High-dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma - a Single Center Retrospective Cohort Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2024-11-24
Completion Date
2025-11-30
Last Updated
2024-11-29
Healthy Volunteers
No
Conditions
Interventions
Bortezomib-bendamustine-melphalan
The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
Locations (1)
Akademiska sjukhuset
Uppsala, Sweden